Antibodies attack the germ or virus of a specific disease and kill them. Determine mother’s HBsAg status as soon as possible. *Unvaccinated = Less than routine series (through 14 months) OR no doses (15 months or older). Bordetella (sometimes given. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Endemic in large parts of the world, PPR causes severe damages to animal production and household economies. CDC twenty four seven. PCV13 and PPSV23 should not be administered during the same visit. 3-4 months,, repeat annually. In the future, the development of a marker vaccine with a robust companion test may help in serosurveillance to identify infection in vaccinated animals to control PPR … Vaccination Schedule This vaccine is recommended for use as early as 3 months of age or older. Always make recommendations by determining needed vaccines based on age (Table 1), determining appropriate intervals for catch-up, if needed (Table 2), assessing for medical indications (Table 3), and reviewing special situations (Notes). 2.2. Unvaccinated persons should complete a 3-dose series at 0, 1–2, 6 months. 11:30-13:00 • Current PPR Vaccines and needs for improvement Adama Diallo, IAEA • Thermostable PPR vaccine: application of rinderpest Jeff Mariner, Tuft experience t to PPR thermostable vaccine production • PPR thermostable vaccine research in IVRI Rabindra Singh, IVRI • Thermostable PPR Vaccine and optimization Ana Carina Silva, IBET Only trivalent OPV (tOPV) counts toward the U.S. vaccination requirements. And some vaccines cause the immune system to develop antibodies against them. Learn how to display current schedules from your website. On the day of vaccination animals were found to be negative for PPR specific antibodies whilst high titre virus neutralising antibodies were detected by second week of vaccination and reached at peak (log 4.76–5.31) on day 28 post vaccination, the day the animals were challenged, in both groups of vaccinated animals (Fig. Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1. Recently, a homologous PPR vaccine has been developed and the vaccine seed is available through the Pan African Veterinary Vaccine Centre (PANVAC) at Debre Zeit, Ethiopia, for Africa, or CIRAD-EMVT at Montpellier, France, for other areas. Immunization Schedule Immunization Schedules. Population # of doses Routine schedule Minimum intervals. ... Peste Des Petits ruminants (PPR) PPR Vaccine: 1 ml S/C: 1 year: November: Rabies: Rabies Post Bite Vaccine: 1 ml S/C: 1 year: 0,3,7,14,28 & 90 days: ALSO READ: The Local and Exotic Breeds of Sheep . 2.5 ml s/c. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. Study population. Vaccinate the lambs on their inner thigh. For MenACWY booster dose recommendations for groups listed under “Special situations” and in an outbreak setting and for additional meningococcal vaccination information, see meningococcal MMWR publications. Age 15 years or older at initial vaccination: 3-dose series at 0, 1–2, 6 months (minimum intervals: 4 weeks between doses 1 and 2/12 weeks between doses 2 and 3/5 months between doses 1 and 3; repeat dose if administered too soon) Age 9 through 14 years at initial vaccination and received 1 dose or 2 doses less than 5 months apart: 1 dose Mass vaccination of sheep and goats in endemic countries might be a pragmatic approach to control PPR in the first phase of disease eradication. What is the public health risk associated with this disease? If mother is HBsAg-positive, administer, 3-dose series at 0, 1–2, 6–18 months (use monovalent HepB vaccine for doses administered before age 6 weeks), Infants who did not receive a birth dose should begin the series as soon as feasible (see. 3-4 months, repeat after 15 days and then annually. CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Doses of OPV administered on or after April 1, 2016, should not be counted. Anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use: Travel in countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj: First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) or military recruits: Adolescent vaccination of children who received MenACWY prior to age 10 years: Note: Menactra should be administered either before or at the same time as DTaP. Age 13–15 years: 1 dose now and booster at age 16–18 years (minimum interval: 8 weeks), Dose 1 at age 8 weeks: 4-dose series at 2, 4, 6, 12 months, Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months), Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart, Age 9–23 months: 2-dose series at least 12 weeks apart, Age 24 months or older: 2-dose series at least 8 weeks apart, Dose 1 at 8 weeks: 4-dose series at 2, 4, 6, 12 months, Dose 1 at 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months), 2-dose series (dose 2 at least 12 weeks after dose 1; dose 2 may be administered as early as 8 weeks after dose 1 in travelers), 1 dose for healthy children age 24–59 months with any incomplete* PCV13 series, 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose), Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart), No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose), No history of either PCV13 or PPSV23: 1 dose PCV13, 1 dose PPSV23 at least 8 weeks later, Any PCV13 but no PPSV23: 1 dose PPSV23 at least 8 weeks after the most recent dose of PCV13, PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent dose of PPSV23, No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose) and a 2nd dose of PPSV23 5 years later, No history of either PCV13 or PPSV23: 1 dose PCV13, 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23), Any PCV13 but no PPSV23: 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks after the most recent dose of PCV13 and dose 2 of PPSV23 administered at least 5 years after dose 1 of PPSV23), PPSV23 but no PCV13: 1 dose PCV13 at least 8 weeks after the most recent PPSV23 dose and a 2nd dose of PPSV23 administered 5 years after dose 1 of PPSV23 and at least 8 weeks after a dose of PCV13. Updated February 2020. Vaccination Methods The vaccine is presented as freeze dried preparation in vials. History of severe allergic reaction to a previous dose of any influenza vaccine or to any vaccine component (excluding egg, see details above), Receiving aspirin or salicylate-containing medications, Age 2–4 years with history of asthma or wheezing, Immunocompromised due to any cause (including medications and HIV infection), Cerebrospinal fluid-oropharyngeal communication, Close contacts or caregivers of severely immunosuppressed persons who require a protected environment, Received influenza antiviral medications within the previous 48 hours.